Tiziana Life Sciences announces results from ozempic, nasal anti-CD3 study

Tiziana Life Sciences (TLSA) announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity, providing a potential novel approach to combat obesity-related inflammation, and liver inflammation and dysfunction. Key Highlights: Nasal anti-CD3 in combination with semaglutide demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity. The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders.